|
Jun 20
|
NGS: the road to personalising cancer care
|
|
Jun 17
|
MGI and SeqOne partner to create end-to-end genomic testing platform
|
|
Jun 13
|
Jefferies Says Buy These 3 Stocks for More Than Double-Digit Returns
|
|
Jun 13
|
Is It Time to Buy May's Worst-Performing Nasdaq Stocks?
|
|
Jun 4
|
Illumina names Everett Cunningham as chief commercial officer
|
|
Jun 3
|
Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential?
|
|
May 29
|
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
|
|
May 28
|
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
|
|
May 28
|
Exact Sciences to Participate in June Investor Conferences
|
|
May 27
|
Hedge Funds are Bullish on This Cancer Stock
|
|
May 24
|
Guardant Stock Climbs As Cancer Test Strides Towards FDA Ok
|
|
May 24
|
FDA panel backs Guardant’s blood test for colon cancer
|
|
May 24
|
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
|
|
May 11
|
Exact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
|
|
May 10
|
Exact Sciences Corp (EXAS) Q1 2024 Earnings: Revenue Growth Amidst Increased Net Loss
|
|
May 10
|
UK NICE backs Exact’s Oncotype cancer genomic test
|
|
May 10
|
Exact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 9
|
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
|
|
May 9
|
Q1 2024 Exact Sciences Corp Earnings Call
|